Author Index
Volumes 29 and 30

A
Abdulla EM, 29:61
Agrawal DK, 29:119, 29:120, 29:175, 29:176, 29:233, 29:234
Aguirre JP, 29:143
Alaranta S, 30:197
Aoki T, 29:21
Arens D, 30:75
Asai Y, 29:165

B
Baram TZ, 30:97
Bast A, 30:209
Beaton ED, 30:217
Beaufort AM, 29:147
Bechem M, 30:143
Bennett BM, 29:29
Berdanier CD, 29:211
Bishop J, 30:19
Blödner R, 30:133
Brien JF, 30:217

C
Campbell IC, 29:61
Capdevila C, 30:159
Carpenter SJ, 29:121
Castellucci A, 29:17
Catelli de Carvalho MH, 29:157
Chézalviel-Guilberrt F, 29:45
Chen Z, 29:111
Cheung PH, 29:179
Cheymol G, 29:45
Chiba S, 29:21
Colombo C, 30:137
Conzentino P, 29:93
Cundy KC, 29:93
Cusma-Pelógia N, 29:157

D
Dabrowicz J, 29:143
Davy JM, 29:45
De Jongste JC, 30:117, 30:149
Dearman RJ, 29:11
Dempster J, 30:1
Dipasquale G, 30:137
Douglas GJ, 30:177
Dutta S, 29:217

E
Eickhoff WM, 29:93, 30:27
Eisenberg EJ, 29:93, 30:27
Evangelista S, 29:17

F
Farmer PS, 30:163
Feigen LP, 30:47
Ferrier G, 30:163
Fiedler U, 30:133
Fortes ZB, 29:157
Frosini M, 29:99
Fryer LR, 30:137
Fujiwara M, 30:169

G
Gabaldón M, 30:159
Garrelds IM, 30:149
Glavin GB, 29:143
Gorelli B, 29:99
Grant GJ, 29:223
Greenham AK, 30:19
Greenspan PD, 30:137
Grimbergen JA, 30:209
Grohs JG, 30:33
Guhennec C, 29:45
Gunji E, 29:105

H
Hadoke PWF, 29:195
Hall AM, 29:143
Handley SL, 29:129
Haston W, 30:137
Hausleithner V, 30:189
Healy C, 30:137
Herd CM, 30:177
Herrmann H-J, 30:133
Hikichi N, 29:105
Hill M, 30:55
Hinds TR, 30:103
Horiuchi M, 30:85
Houwertjes MC, 29:147
Huber S, 30:33
Hulsmann AR, 30:117, 30:149
Hussain T, 30:111

I
Iizuka Y, 29:105
Imaizumi N, 30:169

J
Jamali F, 29:1

K
Kalthof B, 30:143
Kam KL, 30:153
Karatassas A, 30:39
Kashimoto S, 29:37
Kaul N, 30:55
Kays SE, 29:211
Kietzmann M, 30:75
Kimber I, 29:11
Kitagawa S, 30:169
Kitchen I, 29:139
Klassen GA, 30:163
Kleef UW, 29:147
Klinge E, 30:197
Kohen R, 29:185
Konishi M, 30:85
Kostiainen E, 30:197
Kotyuk B, 30:137
Kramer K, 30:209
Kumazawa T, 29:37

Kunitomo M, 30:169

L
Langerman L, 29:223
Lee Chiu S-H, 29:77
Lewis EJ, 30:19
Li R, 30:163
Liu Z, 30:217
Lock EA, 29:211
Löscher W, 30:75
Lubach D, 30:75

M
Maaβ P, 30:75
Maeyama K, 29:105
Manzini S, 29:17
Marks GS, 30:217
Marshall IG, 30:1
Martínez-Sales V, 30:159
Matsuno H, 29:165
Matteini M, 29:99
McBlane JW, 29:129
McKenniff MG, 30:177
McLaughlin BE, 30:217
McLennan PL, 29:203
McMullen M, 30:163
McNeill JH, 29:235
Mehrotra DV, 30:47
Meijer DKF, 29:147
Melchert RB, 29:61
Meyer R, 30:133
Minshall EM, 30:177
Moatti N, 30:69
Morris RG, 30:39
Mosher SJ, 30:163
Muhammad BY, 29:139
Muranaka Y, 29:165
Mustafa SJ, 30:111
Myara I, 30:69

N
Nakamura T, 29:37
Nakashima M, 29:165
Nakatsu K, 30:217
Nicholson NS, 30:47
Nigro D, 29:157
Northover AM, 29:227

O
Oguchi T, 29:37
Oliveira SF, 29:157
O'Neill SK, 29:217
Orfanos A, 30:39

P
Page CP, 30:177
Palmi M, 29:99
Pang SC, 29:29
Panzer-Knodle S, 30:47
Parent-Massin D, 30:203
Parkkisenniemi U-M, 30:197
Pastor G, 30:137
Pellas TC, 30:137
Pepe S, 29:203
Pfaffendorf M, 30:153
Pico I, 30:69
Podesser B, 30:189
Pollak PT, 30:163
Pott L, 30:143
Prior C, 30:1
Pugsley MK, 29:179

R
Raatgeep HR, 30:149
Raberger G, 30:33
Ramanathan S, 29:223
Raptis L, 29:29
Raucy JL, 29:121
Raychaudhuri A, 30:137
Reichert S, 30:133
Riccio MM, 30:177

S
Sadrzadeh SMH, 30:103
Sakurai E, 29:105
Sasaki M, 30:177
Schnellmann RG, 29:211
Schramm M, 30:143
Scivoletto R, 29:157
Seeds EAM, 30:177
Seitelberger S, 30:189
Sgaragli GP, 29:99
Simon WC, 29:29
Singal PK, 30:55
Siveski-Iliskovic N, 30:55
Sjöstrand NO, 30:197
Slezak J, 30:55
Sorenson JRJ, 29:177
Spina D, 30:177
Steger RW, 29:111
Steiert H, 30:189
Swagler AR, 29:211

T
Taite BB, 30:47
Takiguchi Y, 29:165
Thouvenot D, 30:203
Toorenenbergen AWM, 30:149
Triggle CR, 29:217
Turndorf H, 29:223

U
Uematsu T, 29:165
Umemura K, 29:165

V
Valoti M, 29:99
van Acker SABE, 30:209
van der Vijgh WJF, 30:209
van Zwieten PA, 30:153
Vedie B, 30:69
Vermeulen K, 29:223
Vernhet L, 29:45
Vincenzi FF, 30:103
Voss H-P, 30:209

W
Wadsworth RM, 29:195
Wainwright CL, 29:195
Walker MJA, 29:179
Watanabe T, 29:105
Weissenburger J, 29:45
Welder AA, 29:61
Wierda JMKH, 29:147
Wollenek G, 30:189
Wolner E, 30:189
Wright MR, 29:1

Y
Yamaguchi T, 29:37
Yamaguchi Y, 30:169
Yamamoto K-i, 30:85
Yeung PKF, 30:163
Yi S-J, 30:97
Yoshimura K, 30:85

Z
Zakowski MI, 29:223
Zhu BT, 29:85

Subject Index
Volumes 29 and 30

A

Abstracts, 29:119, 29:120, 29:175, 29:176, 29:233, 29:234, 29:235
Adenosine 3′,5′cyclic monophosphate, enzyme immunoassays and, 29:234
Adenosine transporter, erythrocyte, 30:163
Aggregation, platelet, glycoprotein IIb/IIIa antagonists and, 30:47
Airway, human, 30:117, 30:149
Airway epithelium, human airways studies and, 30:117
Airway hyperrresponsiveness, animal model for persistent, 30:177
Airway responsiveness, 30:117
Airway smooth muscle, human airways studies and, 30:117
Allergy
  contact, 29:11
  respiratory, 29:11
Anesthesia
  basal, pentobarbital for, 29:37
  local, mouse tail flick test with, 29:223
Animal models
  antiatherosclerotic agent mice models, 30:169
  elevated X-maze, 29:129
  neutropenia, leukotriene B_4-induced, in, 30:137
Antagonism, competitive/noncompetitive, 29:85
Anti-inflammatory compounds, microvascular permeability and, 29:227
Antigen immunization, airway hyperresponsiveness and, 30:177
Antioxidants
  cyclic voltammetry and oxidative damage in biological samples, 29:185
  free radicals and, 30:55
Anxiety, elevated X-maze and, 29:129
Aorta
  ascending, cardiac output assessment and, 30:33
  glucose and hyperosmolarity on, 30:153
  prostacyclin generation by rat, 30:159
Aorta
  ascending, cardiac output assessment and, 30:33
  glucose and hyperosmolarity on, 30:153
  prostacyclin generation by rat, 30:159
Aortic cholesterol deposition, 30:169
A7r5 cells, electrical field stimulation and, 30:143
Arginine-Glycine-Asparatic acid-Serine, species variation in reaction to platelet aggregation and, 30:47
Arrhthymias, arrhthymia models in rat, 29:179
Atherosclerosis, mice models for, 30:169
Athletes, cocaine, anabolic-androgenic steroids, and, 29:61
ATPases, mulitple membrane, 30:103
3′-Azido-3′-deoxythymidine microdialysis with urea as endogenous recovery marker and, 30:27
AZT. *See* 3′-Azido-3′-deoxythymidine

B

Basilar arterial responses, 29:21
Benzoyl peroxide, percutaneous drug absorption model and, 30:75
Binding site, nitric oxide, 30:217
Biological damage, cyclic voltammetry for evaluation of, 29:185
Blood, histamine and, 29:105
Blood flow, vascularity and drug absorption model, 30:39
BN52021, microvascular permeability and, 29:227
Bovine pulmonary artery, 30:217
Bovine retractor penis muscle, neuromuscular blocking drugs in, 30:197
Bovine serum albumin, 30:217
Bronchial circulation, human airways studies and, 30:117

C

Ca^{2+}-transients, electrical field stimulation of A7r5 vascular smooth muscle cells and, 30:143
Calcium, vasoconstrictions and, 29:17
Cannula
  intracerebroventricular, 29:143
  paraventricular nucleus, 30:97
Cannula-inserting method, modified, 29:21
Cardiac output, measurement of in vivo, 30:33
Cardiac pathologies, free radicals and, 30:55

Cardiotoxicity, cocaine and anabolic-androgenic steroids, 29:61
Cardiovascular drugs, erythrocyte adenosine transport and, 30:163
Cartilage degradation, in vivo model of, 30:19
Cell culture, intracellular delivery of nonpermeant molecules to, 29:29
Cell growth estimation, fluorimetric DNA assay for, 29:120
Cephaloridine, nephrotoxicity induced by, 29:235
Cerebrospinal fluid, HPLC determination of inorganic cation levels in, 29:99
CFU-GM. *See* Colony-forming unit-granulocyte and macrophage
CHAPS. *See* 3-[(3-Cholamidopropyl)dimethylammonio]-1-propane sulfonate 0.3%
Chemiluminescence, nitric oxide and, 29:217, 30:217
2-Chloroadenosine, vascular smooth muscle model and, 30:111
3-[(3-Cholamidopropyl)dimethylammonio]-1-propane sulfonate 0.3%, endothelium inactivation and, 29:157
Cholesterol deposition, aortic, 30:169
Chromatography
  fast protein-liquid, 30:69
  high-performance liquid, 29:99
Chronic intracerebroventricular administration of drugs, 29:143
Cocaethylene, cardiotoxic effects in athletes, 29:61
Cocaine, cardiotoxic effects in athletes, 29:61
Collagenase, endothelium inactivation and, 29:157
Colloidal carbon labelling, 29:227
Colony-forming unit-granulocyte and macrophage, pesticide hematotoxicity and, 30:203
Compound 48/80, histamine receptor antagonists and, 29:105
Computer analysis, electrophysical analysis of transmission at skeletal neuromuscular junction, 30:1
Copper aspirinate, gastric mucosal damage and, 29:177
Coronary artery, vascular smooth muscle model and, 30:111
Corticotropin releasing hormone, cannula implantation in rat and, 30:87
Cyclosporin A, metabolism studies on, 29:77
Cytochrome P450, 29:77
Cytokines, recovery from inflammatory sites in situ, 29:233

D

Dermatopharmacology, in vitro, 30:75
Dexamethasone, percutaneous drug absorption model and, 30:75
Diabetes, experimental, 30:153
Dichlorovinyl-L-cysteine, renal proximal tube cell regeneration model and, 29:211
Diffusion, microdialysis with urea as endogenous recovery marker, 30:27
Distilled water perfusion, endothelium inactivation and, 29:157
DNA assay, cell growth estimation with fluorimetric, 29:120
Dog
  cardiac output assessment in, 30:33
  conscious, 29:45
  physical dependence on morphine induced in, 30:85
Dopamine, microdialysis of, 29:119
Dose-response relationship, spare receptors and, 29:85
Drug absorption, model of vascularity and, 30:39
Drug disposition, lung and, 29:147
Drug interaction, metabolism studies, 29:77

E

EDRF. *See* Endothelium-derived relaxing factor
Electrical field stimulation
  Ca^{2+}-transients in A7r5 vascular smooth muscle cells, 30:143
  human airways studies and, 30:117
  oxidation of exogenous histamine by, 30:149
  programmed, 29:45
Electrocardiogram, telemetry and, 30:209
Electromagnetic flow assessment, cardiac output and, 30:33
Electroporation, liposome fusion vs., 29:29
Enantiomers, racemic drugs and analysis of, 29:1
End-plate current, skeletal neuromuscular junction and, 30:1
End-plate potential, skeletal neuromuscular junction and, 30:1
Endothelial cells, microvascular permeability and, 29:227
Endothelial integrity, prostacyclin generation by rat aortas and, 30:159
Endothelin
  calcium requirements for vasoconstriction and, 29:17
  vasoconstriction induced by, 29:21
Endothelium, vascular function changes in, 29:195
Endothelium-derived relaxing factor
  nitric oxide detection and, 30:217
  vascular function changes and, 29:195
Endothelium inactivation, 29:157
Eosinophilic granulocytes, isolation from human blood, 29:176
Epithelial lining fluid, pharmacokinetic measurement of drugs in, 29:93
Erythrocyte-perfused isolated working heart model of global ischemia, 29:203

Etofenamate, percutaneous drug absorption model and, 30:75
Exercise-training, cocaine and anabolic-androgenic steroids with, 29:61
Extraluminal administration, 29:21

F
Fibrosation, histomorphometry, automated, and, 30:133
Flavonoids, low-density lipoprotein oxidation and, 30:69
FPLC. *See* Chromatography, fast protein-liquid

G
Ganglion-blocking activity, assessment of, 30:197
Gastric mucosal damage, copper aspirinate and, 29:177
Gentamicin, in vivo intrabronchial pharmacokinetic measurements using microdialysis, 93
Global ischemia, 29:203
Glucocorticoid receptor, cannula implantation in rat and, 30:87
Glucose
  plasma microdialysis and, 29:111
  rat isolated aorta and, 30:153
Glyceryl trinitrate biotransformation, liposome-mediated delivery vs. electroporation and, 29:29
Guanosine 3′,5′cyclic monophosphate, enzyme immunoassays for biological fluid estimation of, 29:234
Guanylyl cyclase, nitric oxide detection and, 30:217

H
Handling, telemetry to record electrocardiogram and heart rate, 30:209
Heart rate, telemetry to record electrocardiogram and, 30:209
Hematology, automated, 30:137
Hematopoiesis, pesticide hematotoxicity, 30:203
Hematotoxicity in vitro, pesticide, 30:203
Histamine
  compound 48/80 and histamine receptor antagonists, 29:105
  electrical field stimulation and oxidation of, 30:149
Histamine receptor antagonists, compound 48/80 and, 29:105
Histomorphometry, automated, interstitial reactions of heart and, 30:133
H_2O_2 measurement, 29:175
5-Hydroxytryptamine. *See* Serotonin
Hypercholesterolemia, mice models and, 30:169
Hypothalamus, paraventricular nucleus cannula and, 30:97

I
IgE, mouse, 29:11
Immature hearts, isolated working hearts, 30:189
Inflammation
  cartilage degradation model and, 30:19
  neutropenia, leukotriene B_4-induced, in, 30:137
Inflammatory mediators, microvascular permeability and, 29:227
Interstitial tissue, histomorphometry, automated, and, 30:133
Intracellular delivery, liposome fusion vs. electroporation in, 29:29
Intracerebroventricular cannula, polypropylene mesh for, 29:143
Intraluminal administration, 29:21
Ischemia
  arrhthymia models in rat, 29:179
  global, 29:203
  isolated working heart and, 30:189
Isoflurane, basal anesthesia with, 29:37
Isolated airways
  electrical field stimulation and oxidation of exogenous histamine, 30:149
  methodology review on, 30:117
Isolated heart-lung preparation, drug disposition in lung and, 29:147
Isolated perfused bovine udder, percutaneous drug absorption model, 30:75
Isolated working heart
  global ischemia and, 29:203
  hemodynamic and biochemical changes and, 30:189
Isoproterenol, vascular smooth muscle model and, 30:111

K
Kidney, calcium requirements for vasoconstriction in, 29:17

L
Leukotriene B_4, neutropenia in rat induced by, 30:137
Linoleic acid, mice models and, 30:169
Lipid peroxide, mice models and, 30:169
Lipoprotein, low-density, flavonoid activity on oxidation of, 30:69
Liposomes, electroporation vs. fusion of, 29:29
Losartan, metabolism studies on, 29:77
LTB_4. *See* Leukotriene B_4
Lung
  drug disposition in, 29:147
  in vivo intrabronchial pharmacokinetic measurements using microdialysis, 29:93
Luteinizing hormone, plasma microdialysis and, 29:111
Lymph node assay, local, 29:11

M
Margination, neutropenia, leukotriene B_4-induced, and, 30:137
Metabolism, new drug studies and, 29:77
Metabolite, active, 29:77
Mice, antiatherosclerotic agent screening model, 30:169
Microdialysis
  continuous plasma sampling with, 29:111
  dopamine and, 29:119
  histamine receptor antagonists and, 105
  urea as endogenous recovery marker in, 30:27
  in vivo intrabronchial pharmacokinetics measurements using, 29:93
Microvascular permeability, pro-inflammatory/anti-inflammatory compounds and, 29:227
Middle cerebral artery, ischemia of, 29:165
Miniosmotic pump, morphine and, 30:85
Morphine, physical dependence induced in dogs, 30:85
Mouse, telemetry for electrocardiogram and heart rate in, 30:209
Mouse tail flick test, local anesthetics and, 29:223
Muscle relaxants, drug disposition in lungs by, 29:147
Myocardial dysfunction, free radicals and, 30:55
Myocardial external work, 29:203
Myocardial fibrosis, histomorphometry, automated, and, 30:133
Myocardial oxygen consumption, 29:203
Myocarditis, histomorphometry, automated, and, 30:133
Myoglobin, nitric oxide detection and, 30:217

N
Naloxone, swim stress-induced antinociception and, 29:139
Neonatal hearts, isolated working hearts, 30:189
Nephronal damage, assessments of, 29:235
Nephrotoxicity, cephaloridine-induced, 29:235
Neurite outgrowth, 29:69
Neuromuscular blocking drugs, ganglion-blocking activity of, 30:197
Neurotoxicity, in vitro tests of, 29:69
Neutropenia, leukotriene B_4-induced, 30:137
Nitric oxide, chemiluminescence detection of, 29:217, 30:217
Nonadrenergic noncholinergic response, electrical field stimulation and, 30:149
Norepinephrine, calcium requirements for vasoconstriction and, 29:17

O
Ontogeny, swim stress-induced antinociception and, 29:139
Operation technique, telemetry to record electrocardiogram and heart rate, 30:209
Opioid, swim stress-induced antinociception and, 29:139
Optical isomers, racemic drugs and, 29:1
Org 7617, drug disposition in lungs by, 29:147
Org 9426, drug disposition in lungs by, 29:147
Oxidation potential, measurement of, 29:185
Oxidative stress
  cyclic voltammetry for, 29:185
  free radicals and, 30:55
Oxygen consumption, myocardial, 29:203

P
Paraventricular nucleus cannula, 30:97
Pentobarbital, basal anesthesia with, 29:37
Percutaneous absorption models, 30:75
Peroxidase NADPH oxidation, H_2O_2 measurement and 29:175
Pesticide, hematotoxicity, 30:203
Pharmacokinetics
  aminoglycoside antibiotics, 29:93
  vascularity and drug absorption model, 30:39
Phosphate assay, multiple membrane ATPases, 30:103
Photochemically induced thrombus, middle cerebral artery of the rat with, 29:165
Physical dependence, morphine, 30:85
Plasma
  HPLC in CSF and, 29:99
  microdialysis, 29:111
Plasma membrane, multiple membrane ATPases, 30:103
Plasminogen-plasminogen activator chimera, cerebral thrombosis and, 29:165
Plate reader, multiple membrane ATPases, 30:103
Platelet-activating factor, microvascular permeability and, 29:227
Platelet aggregation, glycoprotein IIb/IIIa antagonists and, 30:47
Polygraphic analysis, physical dependence on morphine in dogs and, 30:85
Progenitors, pesticide hematotoxicity in, 30:203
Prostacyclin, rat aorta generation of, 30:159
Prostaglandin $F_{2\alpha}$, vasoconstriction induced by, 29:21
P450s, fetal, expression of xenobiotic-metabolizing cytochromes, 29:121

R
Rabbit
  airway hyperresponsiveness model, 30:177
  HPLC in CSF and plasma of conscious, 29:99
Rabbit carotid artery, vascular function changes and, 29:195

Racemic drugs, analysis of enantiomers of, 29:1
Rat
  arrhthymia models in, 29:179
  endothelium inactivation and mesenteric arterial bed, 29:157
  erythrocyte-perfused isolated working heart model of global ischemia in, 29:203
  paraventricular nucleus cannula in, 30:97
  plasma microdialysis and, 29:111
Receptors, spare, dose-response profiles and, 29:85
Recovery, microdialysis with urea as endogenous recovery marker, 30:27
Red blood cells, multiple membrane ATPases, 30:103
Reducing agents, oxidative damage in biological samples and, 29:185
Regeneration, model of renal proximal tubule cells, 29:211
Renal proximal tubule cells, in vitro model of regeneration of, 29:211
Reperfusion, arrhthymia models in rat, 29:179
RGDS. *See* Arginine-Glycine-Asparatic acid-Serine
Rocuronium bromide. *See* Org 9426

S

Screening test, erythrocyte adenosine transport, 30:163
Sephadex, microdialysis with urea as endogenous recovery marker and, 30:27
Serotonin, intraluminal/extraluminal administration and, 29:21
Sevoflurane, basal anesthesia with, 29:37
Silver staining, prostacyclin generation by rat aorta and, 30:159
Skeletal muscle neuromuscular junction, electrophysical analysis of transmission at, 30:1
Skin penetration models, 30:75
Sodium deoxycholate, endothelium inactivation and, 29:157
Sodium nitroprusside, nitric oxide detection in, 29:217
Species, glycoprotein IIb/IIIa antagonists and platelet aggregation inhibition, 30:47
Stereoisomerism, 29:1
Steroids, anabolic-androgenic, cardiotoxic effects in athletes, 29:61
Streptozotocin, nitric oxide detection in, 29:217
Stress
  stress-induced antinociception, 29:139
  swimming, 29:139
Substance P, vascular smooth muscle model and, 30:111
SUN9216. *See* Plasminogen-plasminogen activator chimera
Superoxide dismutase/scopoletin, measurement of H_2O_2 and, 29:175
Swimming stress, 29:139

T

Tachycardia, ventricular, canine models for, 29:45
Tail flick test, local anesthetics and, 29:223
Telemetry, electrocardiogram and, 30:209
Testing, predictive, chemical allergens and, 29:11
Theophylline, microdialysis with urea as endogenous recovery marker and, 30:27
Thrombus, photochemically induced, middle cerebral artery of the rat with, 29:165
Tiered tests, neurotoxicity, 29:69
Tissue models, microdialysis with urea as endogenous recovery marker and, 30:27
Tobramycin, in vivo intrabronchial pharmacokinetic measurements using microdialysis, 93
Transplacental induction, fetal P450s and, 29:121

U

Ultrasonic flow assessment, cardiac output and, 30:33

V

Vasodilation, rabbit carotid artery and, 29:195
Voltage-dependent Ca^{2+}-channels, 30:143

W

Working rat heart preparation, 29:37

X

X-maze, elevated, 29:129
Xenobiotic metabolism, fetal P450s and, 29:121